Valentis

Valentis is focused on the creation of innovative cardiovascular therapeutics. The company begins its product development at the stage of a known molecule or protein and applies its expertise in formulation, manufacturing, clinical development and regulatory affairs to create products that fill unmet medical needs.

Valentis currently has two products in development for the treatment of peripheral arterial disease — VLTS 934 and Deltavasc™. VLTS 934 is an investigational poloxamer that appears to improve the function of ischemic tissue. Deltavasc™ is an investigational angiogenesis product that incorporates the Developmentally regulated Endothelial cell Locus-1 (Del-1) gene to stimulate new blood vessel growth (angiogenesis). Based on the results of a Phase IIa trial comparing Deltavasc™ and VLTS 934, Valentis plans to explore reformulation of the Deltavasc™ product and initiate a Phase IIb trial of VLTS 934 in patients with peripheral arterial disease in the second quarter of 2005.

In addition to its own products, Valentis has developed a series of technologies that it has outlicensed to leading biotechnology and pharmaceutical companies. There are currently 10 products in development by licensors of Valentis’ technologies to treat infectious diseases and cancer.

Submit resumes for Burlingame Center positions to jobs@valentis.com

Mail resumes to:
Human Resources
C/o Valentis, Inc.
863A Mitten Road
Burlingame, CA 94010

OR

Fax: 650-652-1990
ATTN: Human Resources

Contact

Corporate Headquarters
863A Mitten Road
Burlingame, CA 94010
T: 650-697-1900
F: 650-652-1990

For more information, please contact: ir@valentis.com

web: Valentis.com